Ginkgo Bioworks Holdings Past Earnings Performance
Past criteria checks 0/6
Ginkgo Bioworks Holdingshan disminuido a un ritmo medio anual de -43.6%, mientras que en la industria Chemicals los ingresos han sido de growing a 11.8% anuales. Los ingresos han sido growing a una tasa media anual de 37.7%.
Key information
-33.4%
Earnings growth rate
-28.2%
EPS growth rate
| Chemicals Industry Growth | 12.9% |
| Revenue growth rate | 27.2% |
| Return on equity | -81.4% |
| Net Margin | -355.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06
With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Ginkgo Bioworks: Avoid For Now
Feb 20Ginkgo: Standardizing Offerings For Growth
Feb 08Ginkgo Bioworks: Increasing Focus On Pharma And Biotech
Jan 12Ginkgo Bioworks launches Ginkgo Enzyme Services
Dec 08Ginkgo, Lygos team up to produce sustainable biobased specialty chemicals
Nov 11Ginkgo, Draper develop new technologies to detect engineered DNA
Oct 17Ginkgo stock rises on acquisition of French biotech Altar
Oct 04Ginkgo Bioworks: Promising Upside But Not Without Risks
Sep 28Ginkgo Bioworks: May The Ginkgo King Grow
Sep 13Is There An Opportunity With Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 50% Undervaluation?
Aug 26Gingko Bioworks: Near-Term Challenges Trump Downstream Economics
Aug 17Ginkgo Bioworks: Time To Buy
Aug 10Biotech Zymergen surges 21% on $300M buyout deal with Ginkgo
Jul 25Revenue & Expenses BreakdownBeta
How Ginkgo Bioworks Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 251 | -893 | 351 | 581 |
| 30 Sep 23 | 315 | -857 | 393 | 629 |
| 30 Jun 23 | 326 | -1,224 | 768 | 746 |
| 31 Mar 23 | 390 | -1,719 | 1,104 | 892 |
| 31 Dec 22 | 478 | -2,105 | 1,403 | 1,053 |
| 30 Sep 22 | 528 | -3,530 | 2,088 | 1,860 |
| 30 Jun 22 | 539 | -2,962 | 1,683 | 1,652 |
| 31 Mar 22 | 438 | -2,347 | 1,279 | 1,414 |
| 31 Dec 21 | 314 | -1,830 | 863 | 1,150 |
| 30 Sep 21 | 197 | -276 | 94 | 226 |
| 30 Jun 21 | 133 | -200 | 75 | 209 |
| 31 Mar 21 | 100 | -175 | 50 | 189 |
| 31 Dec 20 | 77 | -127 | 38 | 160 |
| 31 Dec 19 | 54 | -119 | 29 | 96 |
Beneficios de calidad: DNA actualmente no es rentable.
Creciente margen de beneficios: DNA actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: DNA no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 43.6% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de DNA en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: DNA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Chemicals (-7%).
Return on Equity
Alto ROE: DNA tiene un Rendimiento de los fondos propios negativo (-68.19%), ya que actualmente no es rentable.